**Core tip:** The management of gastrointestinal haemorrhage in children is challenging insofar as the timing and impact of different interventions remains poorly defined. The authors analysed the characteristics and associated interventions associated with mortality as an outcome with gastrointestinial bleeding in children past infancy. Death associated with gastrointestinal haemorrhage was reported in 2% overall albeit less (0.4%) in the cohort with haemorrhage as admitting diagnosis. Patients who died were far less likely to have undergone endoscopy during the admission and more likely to have received octreotide and less likely to have received proton pump inhibitor therapy during the first two days of admission.

INTRODUCTION
============

Gastrointestinal bleeding (GIB) is a foremost indication for emergent diagnostic and therapeutic endoscopy requiring prompt, including disease-specific pharmacotherapy\[[@B1],[@B2]\]. Although acute GIB in adults has been exhaustively studied including epidemiology and predictors of adverse outcomes, there is a paucity of the corresponding evidence in children\[[@B3],[@B4]\]. This deficit hinders the evidence based allocation of resources and the implementation of standardized protocols, potentially adversely impacting outcomes in children.

One of the co-authors, has identified the presence of \> 3 comorbid conditions, presentation to a teaching hospital, the presence of upper GIB; age under 5 years and health coverage with private insurance as independent risk factors associated with an increased rate of hospital admission with GIB\[[@B5]\]. Hemorrhage occurred in 0.5% of all discharges from inpatient care, was more prevalent in males and older than 11 years. Esophageal and intestinal perforation were identified as at highest risk of associated mortality, together accounting for 17% of all patients with GI haemorrhage and who died\[[@B6]\].

Disease classification in adult GIB cannot be extrapolated to the pediatric population. Risk factors identifiable in adults, foremost amongst which are age, non-steroidal anti-inflammatory drug, selective serotonin reuptake inhibitor, aspirin, antiplatelet and anticoagulant therapy and chronic renal and cardiovascular disease, are clearly not applicable to children\[[@B7]\]. Conversely, the impact of predominantly pediatric and especially neonatal disease processes (*e.g*., prematurity) on the risk of GIB remain unknown. This limits the applicability of pre- and postendoscopic predictive scoring systems \[Rockall, Blatchford (aka Glasgow), Addenbrooke\] to identify patients at high risk (need for blood transfusion, surgical intervention, rebleeding and mortality) and those requiring immediate endoscopic intervention as opposed to at low risk who can be safely discharged\[[@B8]-[@B10]\]. The Sheffield Scoring system is, to date the only successful attempt at predicting the need for endoscopic hemostatic intervention based on the clinical presentation, hemodynamic parameters and need for blood products\[[@B11]\]. An understanding of the epidemiologic context of GIB in children holds the promise of directing future research toward improving predictive models of disease outcomes including mortality.

The Pediatric Health Information System (PHIS) database is a repository of diagnostic, therapeutic and procedure records from 48 regional pediatric tertiary centers in the United States that has been in existence since 2004, the data is available in de-identified form to health information management administrators and academicians in the respective institutions.

Herein we report on the PHIS recorded demographic and clinical profile of children with upper or indeterminate gastrointestinal bleeding at admission or during their inpatient course and resulting in death.

MATERIALS AND METHODS
=====================

Data source
-----------

We conducted a retrospective cohort study using data obtained from the PHIS, an administrative database that contains inpatient, emergency department, ambulatory surgery and observation encounter-level data from 49 not-for-profit, tertiary care pediatric hospitals in the United States. The PHIS hospitals are 49 of the largest and most advanced children\'s hospitals in America, and constitute the most demanding standards of pediatric service in America. These hospitals are affiliated with the Children\'s Hospital Association (Overland Park, KS, United States). Data quality and reliability are assured through a joint effort between the Children\'s Hospital Association and participating hospitals. Portions of the data submission and data quality processes for the PHIS database are managed by Truven Health Analytics (Ann Arbor, MI, United States). For the purposes of external benchmarking, participating hospitals provide discharge/encounter data including demographics, diagnoses, and procedures. Nearly all of these hospitals also submit resource utilization data (*e.g*., pharmaceuticals, imaging, and laboratory) into PHIS. Data are de-identified at the time of data submission, and data are subjected to a number of reliability and validity checks before being included in the database. For this study, data from 47 hospitals was included. This study was approved by the Institutional Review Board (16050358).

Study patients
--------------

Children between the ages of 1 and 21 years at the time of admission were eligible for inclusion if they were diagnosed with an upper gastrointestinal bleed (UGIB) or GIB of indeterminate location and admitted as an inpatient or under observation with Emergency Department charges between January 1, 2007 and September 30, 2015. Study participants with UGIB were identified through International Classification of Diseases, Ninth Revision (ICD-9) discharge diagnosis codes (Supplementary Table 1).

Demographic characteristics included age in years at time of admission, sex, race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian, Other, Unknown), discharge disposition (routine/home, expired and rural *vs* urban zip code of residence. Complex chronic conditions (CCCs) were defined using a previously described ICD-9 coding scheme for 9 types of CCCs (neuromuscular, cardiovascular, respiratory, renal, gastrointestinal, hematologic/immunologic, metabolic, congenital or genetic, and malignancy), as well as organ transplant patients and technology dependent patients\[[@B12]\]. A given patient could have could have more than 1 CCC, and the total number of CCCs for each patient was calculated. Chronic liver disease was also identified by ICD-9 diagnosis codes, and coded as a dichotomous variable. The need for packed red blood cell transfusions was used to control for severity of bleeding \[0 = no transfusion, 1 = transfusion(s) received\].

Procedures were identified through ICD-9-CM codes (Supplementary Table 2), and pharmaceuticals and imaging procedures were identified through Clinical Transaction Classification system for revenue codes.

Outcome measures
----------------

The primary outcome of interest in this study was mortality. Secondary outcomes examined include whether or not the patient underwent endoscopy.

Statistical analysis
--------------------

Unadjusted, univariate analyses of the associations between patient characteristics and treatment course with mortality were carried out. Continuous variables were summarized using the median and interquartile ranges (IQR) and compared using the Wilcoxon rank-sum test. Categorical variables were summarized using counts and frequency as a percentage, and compared using the *χ^2^* test of association or Fisher\'s exact test, where appropriate. Complex chronic conditions were treated categorically as the number of complex chronic conditions present in a single patient. The levels of the category were defined as 0 complex chronic conditions, 1 or 2 complex chronic conditions, and 3 or more complex chronic conditions. These levels were chosen after assessing the median and inter-quartile range of the distribution of number of CCCs. Receipt of pharmaceuticals on the first or second day of admission was coded as a dichotomous variable, as was the receipt of packed red blood cell transfusions and platelet transfusions. All procedures were coded as 0 (procedure not billed) or 1 (procedure billed). Unadjusted *P*-values were reported for the univariate analysis.

Adjusted analysis of the association between patient characteristics and treatment course with mortality were examined using multivariable generalized linear mixed models to assess the odds of exposure to treatment among mortality cases (binomial family, logit link). A quasi-likelihood method was used to estimate effects (Laplace approximation). All candidate models were adjusted for potential confounding by age in years at admission, race/ethnicity, and sex and by the need for packed red blood cell transfusions as a surrogate of severity of bleed. Chronic liver disease, comorbid complex chronic conditions, and urban *vs* rural zip code of residence at time of admission were tested as covariates. Other covariates included perforation type injury, administration of proton pump inhibitor (PPI), H~2~RA, octreotide, and vasopressin pharmaceuticals on the first or second day of admission and endoscopic procedures performed. Interactions between vasopressin and shock, endoscopy and chronic liver disease, and endoscopy and CCCs were also tested to investigate potential effect modification. To account for increased variability due to clustering within hospitals, a random intercept was included using a unique hospital ID. Model selection was carried out using -2 log likelihood tests with the *χ^2^* approximation. Individual covariates were tested by approximation to the *Z*-value. The Holm procedure was used to account for multiple testing of covariates for each outcome, and the adjusted *P*-values are reported for the significance test of model covariates. An adjusted, two-tailed *P* \< 0.05 was considered statistically significant. All analyses were performed using the R statistical package, v.3.2.3.

RESULTS
=======

Descriptive statistics
----------------------

There were 19528 patients with upper or indeterminate GIB discharged between January 1, 2007 and September 30, 2015 (Table [1](#T1){ref-type="table"}). Overall, 54.6% of patients were male, and the median age was 9 years (IQR 4-15). Nearly half (49.68%) of the patients had no documented CCCs, 30.32% had 1 or 2 CCCs, and 20.01% had 3 or more CCCs. The most common CCC was gastrointestinal conditions (28.22%), followed by technology dependence\[[@B12],[@B13]\] (20.24%) and neurologic and neuromuscular disorders (13.90%). Of the patients included in the analysis, 33.78% experienced hematemesis, 40.97% melena, 12.18% had gastroesophageal reflux (GER), 3.73% experienced shock, 3.56% experienced sepsis, and 18.45% required packed red blood cell transfusion while 5.09% required a platelet transfusion. Most patients resided in an urban area (85.31%), although a small portion of the data was missing (2.16%).

###### 

Patient characteristics by principal and secondary diagnosis of gastrointestinal bleeding *n* (%)

                                       **GI bleed**   **Overall (*n* = 19528)**   ***P* value**    
  ------------------------------------ -------------- --------------------------- ---------------- -----------
  Age in years (IQR)                   10 (4, 15)     9 (4, 15)                   9 (4, 15)        \< 0.0001
  Gender                                                                                           \< 0.0001
  Female                               2925 (43.44)   5941 (46.43)                8866 (45.40)     
  Male                                 3808 (56.56)   6854 (53.57)                10762 (55.11)    
  Race                                                                                             \< 0.0001
  Non-Hispanic White                   3608 (53.59)   6596 (51.55)                10204 (52.25)    
  Non-Hispanic Black                   1180 (17.53)   2257 (17.64)                3437 (17.60)     
  Hispanic                             1159 (17.21)   2580 (20.16)                3739 (19.15)     
  Asian                                251 (3.73)     332 (2.59)                  583 (2.99)       
  Other                                412 (6.12)     779 (6.09)                  1191 (6.10)      
  Unknown                              123 (1.83)     251 (1.96)                  374 (1.92)       
  Urban/rural                                                                                      0.1247
  Urban                                5730 (85.10)   10930 (85.42)               16660 (85.31)    
  Rural                                873 (12.97)    1573 (12.29)                2446 (12.53)     
  Unknown                              130 (1.93)     292 (2.28)                  422 (2.16)       
  Complex chronic conditions                                                                       \< 0.0001
  0                                    3767 (55.95)   5969 (46.65)                9736 (49.86)     
  1-2                                  1771 (26.30)   4328 (33.83)                6099 (31.23)     
  **≥** 3                              1195 (17.75)   2498 (19.52)                3693 (18.91)     
  GIH symptoms                                                                                     
  Hematemesis                          2333 (34.65)   4263 (33.32)                6596 (33.78)     0.0635
  Melena                               1983 (29.45)   6018 (47.03)                8001 (40.97)     \< 0.0001
  Hypovolemia                          52 (0.77)      90 (0.70)                   142 (0.73)       0.5956
  Pharmaceutical Interventions                                                                     
  PPI on day 0 or 1                    4473 (66.43)   6038 (47.19)                10511 (53.83)    \< 0.0001
  H2RA on day 0 or 1                   1301 (19.32)   2715 (21.22)                4016 (20.57)     0.0019
  Erythromycin on day 0 or 1           197 (2.93)     313 (2.45)                  510 (2.61)       0.0511
  Vasopressin on day 0 or 1            15 (0.22)      142 (1.11)                  157 (0.80)       \< 0.0001
  Octreotide on day 0 or 1             349 (5.18)     439 (3.43)                  788 (4.04)       \< 0.0001
  Diagnostic Imaging                                                                               
  Meckel\'s Scan day 0-2               497 (7.38)     378 (2.95)                  875 (4.48)       \< 0.0001
  Abdomen CT day 0-2                   425 (6.31)     1298 (10.14)                1723 (8.82)      \< 0.0001
  Abdomen MRI day 0-2                  44 (0.65)      170 (1.33)                  214 (1.10)       \< 0.0001
  Arteriography day 0-2                75 (1.11)      93 (0.73)                   168 (0.86)       0.0070
  Surgical interventions                                                                           
  Laparotomy, exploratory              23 (0.34)      44 (0.34)                   67 (0.34)        0.9999
  Laparotomy, other                    2 (0.03)       19 (0.15)                   21 (0.11)        0.0191
  Laparoscopy                          54 (0.80)      96 (0.75)                   150 (0.77)       0.7303
  EGD                                  2304 (34.22)   2317 (18.11)                4621 (23.66)     \< 0.0001
  Other endoscopy                      845 (12.55)    845 (6.6)                   1690 (8.65)      \< 0.0001
  Transcatheter embolization           8 (0.12)       8 (0.06)                    16 (0.08)        0.1977
  Ligation, esophag. varices           0 (0.0)        5 (0.04)                    5 (0.03)         0.1719
  Ligation, gastric varices            1 (0.01)       5 (0.04)                    6 (0.03)         0.6713
  Packed red blood cell transfusions   1265 (18.79)   2337 (18.26)                3602 (18.45)     0.3808
  Platelet transfusions                194 (2.88)     799 (6.24)                  993 (5.09)       \< 0.0010
  ICU stay as part of encounter        880 (13.07)    2328 (18.19)                3208 (16.43)     \< 0.0001
  Chronic liver disease                171 (2.54)     400 (3.13)                  571 (2.92)       0.0234
  GIH present on admit                 4980 (73.96)   8585 (67.10)                11084 (56.76%)   \< 0.0001
  Shock                                144 (2.14)     584 (4.56)                  728 (3.73)       \< 0.0001
  Sepsis                               30 (0.45)      666 (5.21)                  696 (3.56)       \< 0.0001
  Hospital lOS (IQR)                   2 (1, 4)       3 (2, 7)                    3 (1, 6)         \< 0.0001
  Day of EGD                           1 (0, 2)       2 (1, 3)                    1 (0, 2)         \< 0.0001
  Mortality                            25 (0.37)      379 (2.96)                  404 (2.07)       \< 0.0001

IQR: Interquartile ranges; GER: Gastroesophageal reflux; PPI: Proton pump inhibitor; H~2~RA: H~2~-receptor antagonists; CT: Computed tomography; MRI: Magnetic resonance imaging; GIB: Gastrointestinal bleeding; EGD: Esophagogastroduodenoscopy.

Overall mortality rate was 2.07% with 0.37% mortality among patients with principal diagnosis of GIB and 2.96% among patients with secondary diagnosis of GIB. The median time until death was 19 d (5, 49). For all patients, 21.53% of deaths occurred within the first 3 d of admission, and 31.9% occurred within 7 d of admission. When considering only the mortalities in which GIB was the principal diagnosis, 48% (12 of 25 principal diagnosis GIB mortalities) died within the first 3 d of admission, and 64% expired within 7 d of admission. Among secondary diagnosis patients, 19.8% died with 3 d of admission, and 29.8% died within 7 d of admission. Although the majority of patients were male, females and males had similar mortality rates (50% of mortalities were male). There were apparent racial/ethnic distributional differences, with non-Hispanic Whites being the only group that comprised a smaller proportion of the mortalities than the surviving cases.

Early intervention with pharmaceuticals was more frequent among mortality cases (Table [2](#T2){ref-type="table"}). Receipt of PPI on the first or second day of admission occurred in 53.83% of patients, with higher usage among mortalities (68.56% *vs* 53.31%). H~2~RA were administered on the first or second day of admission in 20.57% of patients, with higher usage in mortality than non-mortality cases (37.62% *vs* 20.20%). Octreotide was only used in 4.04% of patients; 19.80% of patients who died received octreotide on the first or second day of admission, and 3.70% surviving cases received octreotide. Vasopressin was only given to 0.80% of patients; 24.50% of the mortality cases and 0.30% of surviving cases received vasopressin on the first or second day of admission.

###### 

Univariate analysis of factors affecting mortality *n* (%)

                                      **Survived (*n* = 19124)**   **Died (*n* = 404)**   **Overall (*n* = 19528)**   ***P* value**
  ----------------------------------- ---------------------------- ---------------------- --------------------------- ---------------
  Age in years (IQR)                  9 (4, 15)                    8 (3, 15)              9 (4, 15)                   0.2997
  Gender                                                                                                              0.0679
  Female                              8864 (46.35)                 202 (50)               9066 (46.43)                
  Male                                10460 (54.70)                202 (50)               10662 (54.60)               
  Race                                                                                                                0.0005
  Non-Hispanic White                  10036 (52.48)                168 (41.58)            10204 (52.25)               
  Non-Hispanic Black                  3358 (17.56)                 79 (19.55)             3437 (17.60)                
  Hispanic                            3646 (19.07)                 93 (23.02)             3739 (19.15)                
  Asian                               565 (2.95)                   18 (4.46)              583 (2.99)                  
  Other                               1156 (6.04)                  35 (8.66)              1191 (6.10)                 
  Unknown                             363 (1.90)                   11 (2.72)              374 (1.92)                  
  Urban/rural                                                                                                         0.2524
  Urban                               16324 (85.36)                336 (83.17)            16660 (85.31)               
  Rural                               2385 (12.47)                 61 (15.10)             2446 (12.53)                
  Unknown                             415 (2.17)                   7 (1.73)               422 (2.16)                  
  Complex chronic conditions          \< 0.0001                                                                       
  0                                   9689 (50.66)                 12 (2.97)              9701 (49.68)                
  1-2                                 5825 (30.46)                 95 (23.51)             5920 (30.32)                
  **≥** 3                             3610 (18.88)                 297 (73.51)            3907 (20.01)                
  GIH symptoms                                                                                                        
  Hematemesis                         6508 (34.03)                 88 (21.78)             6596 (33.78)                \< 0.0001
  Melena                              7899 (41.30)                 102 (25.25)            8001 (40.97)                \< 0.0001
  Hypovolemia                         131 (0.69)                   11 (2.72)              142 (0.73)                  0.0002
  GER                                 2329 (12.18)                 50 (12.38)             2379 (12.18)                0.9653
  Pharmaceutical interventions                                                                                        
  PPI first 24 h                      10234 (53.51)                277 (68.56)            10511 (53.83)               \< 0.0001
  H~2~RA first 24 h                   3864 (20.20)                 152 (37.62)            4016 (20.57)                \< 0.0001
  Erythromycin first 24 h             480 (2.51)                   30 (7.43)              510 (2.61)                  \< 0.0001
  Vasopressin first 24 h              58 (0.30)                    99 (24.50)             157 (0.80)                  \< 0.0001
  Octreotide first 24 h               708 (3.70)                   80 (19.80)             788 (4.04)                  \< 0.0001
  Surgical interventions                                                                                              
  Laparotomy, exploratory             54 (0.28)                    13 (3.22)              67 (0.34)                   \< 0.0001
  Laparotomy, other                   16 (0.08)                    5 (1.24)               21 (0.11)                   \< 0.0001
  Laparoscopy                         144 (0.75)                   6 (1.49)               150 (0.77)                  0.1347
  EGD                                 4569 (23.89)                 52 (12.87)             4621 (23.66)                \< 0.0001
  Other endoscopy                     1638 (8.57)                  52 (12.87)             1690 (8.65)                 0.0031
  Transcatheter embolization          14 (0.07)                    2 (0.50)               16 (0.08)                   0.0423
  Ligation, esophag. varices          4 (0.02%)                    1 (0.25%)              5 (0.03)                    0.0993
  Ligation, gastric varices           6 (0.03)                     0 (0.00)               6 (0.03)                    0.9999
  Diagnostic imaging                                                                                                  
  Meckel\'s Scan day 0-2              873 (4.56)                   2 (0.50)               875 (4.48)                  0.0001
  Abdomen CT day 0-2                  1675 (8.76)                  48 (11.88)             1723 (8.82)                 0.0356
  Abdomen MRI day 0-2                 212 (1.11)                   2 (0.50)               214 (1.10)                  0.3340
  Arteriography day 0-2               163 (0.85)                   5 (1.24)               168 (0.86)                  0.4031
  Packed red blood cell Transfusion   3361 (17.57)                 241 (59.65)            3602 (18.45)                \< 0.0001
  Platelet transfusion                819 (4.28)                   174 (43.07)            993 (5.09)                  \< 0.0001
  ICU stay as part of encounter       2863 (14.97)                 345 (85.40)            3208 (16.43)                \< 0.0001
  Chronic liver disease               536 (2.80)                   35 (8.66)              571 (2.92)                  \< 0.0001
  GIB Present on admit                13386 (70.00)                179 (44.31)            11084 (56.76)               \< 0.0001
  Principal Dx GIB                    6708 (35.07)                 25 (6.18)              6733 (34.48)                \< 0.0001
  Sepsis                              516 (2.70)                   180 (44.55)            696 (3.56)                  \< 0.0001
  Shock                               562 (2.94)                   166 (41.09)            728 (3.73)                  \< 0.0001
  Hospital LOS (IQR)                  3 (1, 6)                     19 (5, 49)             3 (1, 6)                    \< 0.0001
  Day of EGD                          1 (0, 2)                     3 (1, 14)              1 (0, 2)                    \< 0.0001

IQR: Interquartile ranges; GER: Gastroesophageal reflux; PPI: Proton pump inhibitors; H~2~RA: H~2~-receptor antagonists; CT: Computed tomography; MRI: Magnetic resonance imaging; GIB: Gastrointestinal bleeding; EGD: Esophagogastroduodenoscopy.

Table [3](#T3){ref-type="table"} displays the top admitting diagnosis codes for mortalities and non-mortalities. Mortalities included several diagnosis codes not related to GI symptoms, including dyspnea and respiratory abnormalities, cardiac arrest, pneumonia, diseases of white blood cells, and respiratory failure. Non-mortalities more frequently carried GI-specific admitting diagnoses.

###### 

Top 10 admitting diagnoses for mortalities and non-mortalities

  **ICD-9 code**    **ICD-9 code description**                    ***n* (%)**
  ----------------- --------------------------------------------- --------------
  Mortalities                                                     
  780.60            Fever                                         32 (7.92)
  786.09            Other dyspnea and respiratory abnormality     23 (5.69)
  787.03            Vomiting alone                                15 (3.71)
  03.89             Unspecified septicemia                        14 (3.47)
  578.0             Hematemesis                                   13 (3.22)
  427.5             Cardiac arrest                                13 (3.22)
  578.9             Hemorrhage of GI tract, unspecified           12 (2.97)
  486.0             Pneumonia, organism unspecified               11 (2.72)
  288.00            Diseases of white blood cells                 10 (2.48)
  518.81            Acute respiratory failure                     10 (2.48)
  Non-mortalities                                                 
  578.0             Hematemesis                                   3058 (15.99)
  578.1             Blood in Stool                                2750 (14.38)
  578.9             Hemorrhage of GI tract, unspecified           1289 (6.74)
  789.00            Other symptoms involving abdomen and pelvis   755 (3.95)
  787.03            Vomiting alone                                748 (3.91)
  N/A               Not available or Missing                      707 (3.70)
  780.60            Fever                                         559 (2.92)
  276.51            Dehydration                                   515 (2.69)
  787.91            Diarrhea                                      500 (2.61)
  2859              Anemia                                        292 (1.53)

GI: Gastrointestinal; ICD-9: International Classification of Diseases, Ninth Revision.

Multivariable analysis
----------------------

**Factors associated with mortality in all GIB diagnoses:** After adjustment for other covariates, race was not significantly associated with mortality in patients with a primary diagnosis of UGIB or unspecified GIB (adjusted *P* = 0.999). Although the majority of patients were male, mortality tended to be higher in females; however, gender was not significantly associated with mortality (adjusted *P* = 0.339). Age was also not significantly associated with mortality (adjusted *P* = 0.999). These covariates were retained in the model for their role as potential confounders. Urban *vs* rural zip code of residence, H~2~RA within the first or second day of admission, and the interaction between endoscopy and chronic liver disease were not statistically significant and did not improve fit, thus were removed from the model \[*χ^2^* (4) = 4.505, *P* = 0.342\]. Furthermore, chronic liver disease, and the interaction between endoscopy and CCCs were not significant and did not significantly improve model fit and were also removed from the final model \[*χ^2^* (3) = 4.612, *P* = 0.203\]. Although PPI on the first or second day of the encounter was not significant after correcting for multiple testing, the inclusion of this variable significantly improved model fit \[*χ^2^* (1) = 5.451, *P* = 0.020\].

Those patients who died were far less likely to have undergone an endoscopic procedure (OR = 0.489, 95%CI: 0.356-0.672, *P* \< 0.0001), indicating a protective association with endoscopy. Mortalities were also less likely to have a GIB documented as present on admission (OR = 0.464, 95%CI: 0.362-0.596, *P* \< 0.0001), and less likely to have had the GIB as the principal diagnosis for the encounter (OR = 0.266 95%CI: 0.165-0.429, *P* \< 0.0001). This may suggest that GIB more commonly complicates inpatient stays for patients admitted or being primarily treated for other conditions. PPI administration on the first or second day of admission tended to be protective; however, the effect was not statistically significant after correction for multiple testing (OR = 0.723, 95%CI: 0.552-0.947, *P* = 0.074).

The odds of having 1 or 2 CCCs compared to 0 CCCs were 9.090 times higher for mortalities over non-mortalities (95%CI: 4.907-16.841, *P* \< 0.0001), and the odds of having 3 or more CCCs compared to 0 CCCs was 27.338 (95%CI: 14.940-50.027, *P* \< 0.0001) times higher for mortalities over non-mortalities. Mortalities have significantly increased odds of having multiple complex chronic conditions. Table [4](#T4){ref-type="table"} differentiates the presence of concomitant CCC in patients with GIB as principal as opposed to secondary diagnosis whereas Table [5](#T5){ref-type="table"} summarizes the distribution of CCCs between mortality and non-mortality patients.

###### 

Complex chronic conditions by principal and secondary diagnosis of gastrointestinal bleeding *n* (%)

                              **Principal Dx is GI bleed (*n* = 4521)**   **Secondary Dx is GI bleed (*n* = 15007)**   ***P* value**
  --------------------------- ------------------------------------------- -------------------------------------------- ---------------
  GI flag                     1681 (24.39)                                3892 (15.39)                                 \< 0.0001
  Cardiovascular flag         513 (7.44)                                  1192 (4.71)                                  \< 0.0001
  Hem/immunologic flag        422 (6.12)                                  1392 (5.5)                                   \< 0.0001
  Malignancy                  284 (4.12)                                  1015 (4.01)                                  \< 0.0001
  Metabolic flag              258 (3.74)                                  1015 (4.01)                                  \< 0.0001
  Neurologic/neuromusc flag   972 (14.1)                                  1743 (6.89)                                  0.1234
  Congenital/genetic flag     727 (10.55)                                 1192 (4.71)                                  0.0010
  Renal/urologic flag         249 (3.61)                                  811 (3.21)                                   \< 0.0001
  Respiratory flag            244 (3.54)                                  601 (2.38)                                   0.0005
  Technology depend flag      1353 (19.63)                                2599 (10.28)                                 0.7331
  Transplant flag             318 (4.61)                                  578 (2.29)                                   0.5374

GI: Gastrointestinal.

###### 

Complex chronic conditions by discharge disposition *n* (%)

                              **Survived (*n* = 19124)**   **Died (*n* = 404)**   ***P* value**
  --------------------------- ---------------------------- ---------------------- ---------------
  Gastrointestinal flag       5351 (27.98)                 159 (39.36)            \< 0.0001
  Cardiovascular flag         1543 (8.07)                  162 (40.10)            \< 0.0001
  Hem/immunologic flag        1662 (8.69)                  152 (37.62)            \< 0.0001
  Malignancy                  1164 (6.09)                  135 (33.42)            \< 0.0001
  Metabolic flag              1138 (5.95)                  135 (33.42)            \< 0.0001
  Neurologic/neuromusc flag   2570 (13.44)                 145 (35.89)            \< 0.0001
  Congenital/genetic flag     1838 (9.61)                  81 (20.05)             \< 0.0001
  Renal/urologic flag         927 (4.85)                   133 (32.92)            \< 0.0001
  Respiratory flag            780 (4.08)                   65 (16.09)             \< 0.0001
  Technology depend. flag     3710 (19.40)                 242 (59.90)            \< 0.0001
  Transplant flag             802 (4.19)                   94 (23.27)             \< 0.0001

Mortalities had significantly higher odds of perforation as well (OR = 5.505, 95%CI: 1.717-17.650, *P* = 0.021). There was a significant association between mortality and diagnosis of sepsis during the encounter and mortality (OR = 2.583, 95%CI: 1.823-3.659, *P* \< 0.0001). Mortalities had substantially higher odds of shock (OR = 3.585, 95%CI: 2.489-5.163, *P* \< 0.0001), but this effect was modified by vasopressin. Mortalities had 4.834 times the odds of experiencing shock and receiving vasopressin compared to shock alone over non-mortalities (95%CI: 2.729-8.562, *P* \< 0.0001). Vasopressin is primarily used to treat shock in critically ill children\[[@B3]\]. Higher mortality in patients receiving vasopressin and shock does not necessarily represent a causal chain - it may merely be highlighting the pattern that severe cases of shock were more frequently given vasopressin. The strength of the association is striking and the administration of vasopressin in shock cases did not associate with significantly improved outcomes. The effect of vasopressin on GI bleeds and shock warrants further investigation in pediatric patients.

Receiving octreotide or vasopressin was significantly associated with having a portal hypertension diagnosis \[*χ^2^* (1) = 3261.5, *P* \< 0.0001\], and with having varices with bleeding \[*χ^2^* (1) = 2477.2, *P* \< 0.0001\]. Receiving octreotide within the first 24 h was associated with a 2.934 fold increase in odds of death (OR = 2.936, 95%CI: 1.981-4.351, *P* \< 0.0001). This is more likely an indicator of severity of illness and early treatment as more severe patients who would eventually expire received more aggressive treatment.

**Factors affecting mortality in GIB as principal, admitting or present on admit:** As a sensitivity analysis, we isolated only those patients whose principal diagnosis was a GIB, or the GIB was present on admit or the admitting diagnosis to see if the trends observed associations pertained to a more refined group of GIB patients (*n* = 15539, 185 mortalities). After applying the model-fitting procedure, the final model yielded results similar to those observed for the full cohort of GIB patients in PHIS, with most of the associations being strengthened (the exception being CCCs), suggesting the secondary GIB may have biased estimates toward the null Age, race, and gender were not statistically significantly associated with mortality when controlling for other covariates (*P* = 0.999, *P* = 0.999, *P* = 0.937, respectively). Again, residing in an urban area, administration of H~2~RA on day 0 or 1, chronic liver disease, and the interaction between endoscopy and chronic liver disease were not significant and did not improve model fit \[*χ^2^* (5) = 4.527, *P* = 0.476\]. Perforation-type injury and GIB present on admission were not significant and subsequently removed from the final model \[*χ^2^* (2) = 3.644, *P* = 0.162\].

In this smaller cohort, patients who died were even less likely to have undergone an endoscopic procedure (OR = 0.327, 95%CI: 0.202-0.539, *P* \< 0.0001). Mortalities had marginally lower odds of receipt of a PPI on the first or second day of admission (OR = 0.613, 95%CI: 0.417, 0.902, *P* = 0.051). Receiving octreotide on the first or second day of admission was associated with an increase in odds of death (OR = 2.219, 95%CI: 1.286-3.831, *P* = 0.025).

The strength of the association with CCCs was not quite as pronounced in the smaller cohort. The odds of having 1 or 2 CCCs compared to 0 CCCs were 8.710 times higher for mortalities over non-mortalities (95%CI: 3.861-19.651, *P* \< 0.0001), and the odds of having 3 or more CCCs compared to 0 CCCs was 24.098 (95%CI: 10.778-53.884, *P* \< 0.0001) times higher for mortalities over non-mortalities. Mortalities have significantly increased odds of having multiple complex chronic conditions in the smaller cohort, but the associations are less strong.

There was a significant association between mortality and diagnosis of sepsis during the encounter (OR = 2.040, 95%CI: 1.197-3.477, *P* = 0.044). Mortalities had substantially higher odds of shock (OR = 5.426, 95%CI: 3.212-9.168, *P* \< 0.0001) but this effect was modified by vasopressin, with a stronger association marked in the smaller cohort. Mortalities had 12.090 times the odds of experiencing shock and receiving vasopressin compared to shock alone over non-mortalities (95%CI: 5.327-27.442, *P* \< 0.001).

**Factors associating with endoscopy:** In a separate model, we examined the association between various patient characteristics and whether or not the patient underwent endoscopy. A total of 5939 patients received endoscopy. Supplementary Table 2 stratifies therapeutic endoscopy type. The vast majority of endoscopic procedures were esophagogastroduodenoscopy. We adjusted the model for those factors relating to mortality and severity (shock, sepsis, packed red blood cell transfusion, GIB diagnosis present on admit, and GIB diagnosis as principal diagnosis). We found that those patients with chronic liver conditions were more likely to undergo endoscopy (OR = 2.378, 95%CI: 1.970-2.869, *P* \< 0.0001), which may explain partially why this factor was not found significant in the mortality model. If endoscopy is protective and patients with chronic liver disease are more likely to undergo endoscopy, it stands to reason that they will then be less likely to die. We also found that living in a rural area was positively associated with endoscopy compared to living in an urban area (OR = 1.196, 95%CI: 1.076-1.329, *P* = 0.007). Compared to non-Hispanic white patients, Hispanics were 18.5% less likely to have undergone an endoscopic procedure (OR = 0.815, 95%CI: 0.737-0.900, *P* = 0.001). Age was also significantly associated with endoscopy, with a 6.39% increase in odds for every additional year (OR = 1.064, 95%CI: 1.058-1.070, *P* \< 0.0001). Patients with 1 or 2 CCCs did not have increased odds of endoscopy (*P* = 0.999), but those with 3 or more had a 24.53% reduction in the odds of endoscopy (OR = 0.755, 95%CI: 0.686-0.830, *P* \< 0.0001). Perforation injuries were also far less likely to undergo endoscopy (OR = 0.169, 95%CI: 0.116-0.247). GIBs as the principal diagnosis were associated with higher odds of endoscopy (OR = 2.626, 95%CI: 2.448-2.817, *P* \< 0.0001). Those who underwent endoscopy were more likely to have experienced shock (OR = 1.752, 95%CI: 1.409-2.179, *P* \< 0.0001), but less likely to have become septic (OR = 0.473, 95%CI: 0.370-0.604, *P* \< 0.0001).

DISCUSSION
==========

This is the first study describing the demographic and clinical characteristics of pediatric patients with GI hemorrhage in tertiary referral pediatric centers. In our cohort more than 75% of patients with GIB presented with hematemesis or blood in the stool. Mortality at, or before 3 d was more likely in patients with GIB as a primary diagnosis, and in this subgroup mortality was highest in the first 7 d of admission. The mortality in patients with a principal diagnosis of GIB was 0.37% whereas the mortality in patients with GIB as a secondary diagnosis was 2.96% signalling that GIB can be a terminal event in children with other severe disease processes.

We also found that in pediatric patients, race, gender, and age were not significantly associated with mortality. Death was most strongly associated with shock, sepsis, multiple complex chronic conditions and use of vasopressin and octreotide, although these pharmaceutical treatments may represent aggressive treatment of haemorrhage (octreotide) or hemodynamic support (vasopressin) for severely ill patients.

Our observations in children are analogous to published studies in adults showing mortality to be many times higher for upper GIB complicating the inpatient course in the presence of comorbidities\[[@B14]\]. In our cohort, we could not determine whether the increased mortality in patients with multiple chronic comorbidities was related to the GIB event or was intrinsic to the medical frailty of these patients. However, we observed the association to be consistent between both patients with any diagnosis of GIB as well as the more focused group with primary GIB diagnosis. GIB patients with multiple chronic illnesses are at incremental risk, and mortality in patients with primary GIB is significantly associated, albeit less robustly, with multiple complex chronic conditions than children with a secondary diagnosis. More specifically, our observations support the validity of the Sheffield Scoring System which identifies significant pre-existing condition as an independent determinant of the need for therapeutic endoscopy\[[@B11]\].

The observed increased mortality associated with GIB with chronic comorbidities and infection can be explained through several mechanisms. For example, the strong relationship between sepsis and mortality with GIB may relate to the development of disseminated intravascular coagulation that would exacerbate bleeding. Conversely septicemia may be a terminal complication in a child with multi-organ injury from bleeding-hypovolemic shock. Similarly oncologic comorbidities signal a greater degree of overall debility as a function of immunosuppression, impaired fluid and electrolyte balance, poor nutrition, suppressed erythropoiesis and several potential iatrogenic factors impacting homeostatic responses.

We could not, in this analysis, confirm a relationship between GIB related admission mortality and distance travelled to care as defined by rural compared with urban address; a significant relationship was noted when analysis was performed looking at all GIB associated mortality, this was not borne out when the cohort was defined by admitting or principal diagnosis.

Endoscopy was associated with lower mortality, as was the administration of a PPI on the first or second day of admission. Mortality was also lower for patients with GIB that was present on admission or the principal diagnosis, supporting the impression that GIB can be viewed as an ominous complication defining a generally more dismal outcome in children.

We did find that certain patients were more likely to undergo endoscopy. Endoscopy during admission with GIB diagnosis was significantly protective (OR = 0.49); the effect was most pronounced in children with a principal diagnosis of GIB (OR = 0.28). Chronic liver disease patients were much more likely to undergo endoscopy, which may explain why this comorbidity, in turn, was not found to be significantly associated with mortality although it is a known risk factor. Racial and urban *vs* rural differences were also noted. Hispanics were significantly less likely to undergo endoscopy during admission with GIB and mortality with GIB is lowest in non-Hispanic white children.

The sensitivity analysis yielded similar results when we focused on a smaller cohort of patients with principal diagnosis of GIB, admitting diagnosis of GIB, or GIB present on admit. The purpose of examining the smaller cohort was to exclude as much as possible those secondary GIB cases that arose as complication of a non-GIB disease course. We found even stronger association for most of the covariates, suggesting possible masking and bias toward the null by including more complex and severely ill patients whose hospital stay was not chiefly attributed to a GIB.

As a retrospective observational study using primarily administrative billing data, there are several limitations to the study. The use of ICD-9 diagnosis codes has been shown to be sensitive and specific for some conditions and procedures including gastrointestinal hemorrhage\[[@B15]\] but are unknown for all ICD-9 codes. Coding practices may also vary within hospitals, and the reliability of these codes depends on proper documentation. Substantial risk factors or severity factors may be missing from the data.

In summary, we have reported on the mortality associated with admission for acute GI hemorrhage in children. Gastrointestinal hemorrhage can be fatal but more often defines deterioration in a child with other, especially multiple, comorbidities. Intense pharmacologic support associates with mortality underscoring the escalation of therapy with increased clinical compromise. Endoscopy was consistently protective from mortality, and the timing, scope and therapeutic goals of endoscopy in GI hemorrhage are still to be precisely defined and universally applied in children. Emerging scoring systems and prospective implementation of such may go some way to identifying and stratifying the protective effects of endoscopy in children. This study offers new impetus to aggressive, including endoscopic, management.
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The presentation, course and outcome of gastrointestinal haemorrhage in children compared with adults remains poorly characterized; little is known about factors related mortality associated with gastrointestinal bleeding in children and this impedes an evidence based approach to management in this population.
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Upper gastrointestinal haemorrhage, younger age at presentation and multiple comorbidities are associated with admission, whereas chronic illness, need for transfusion and large haemoglobin drop signal the need for endoscopy during admission. Mortality with gastrointestinal haemorrhage is most frequently associated with esophageal or intestinal perforation.
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the prognosis for patients with gastrointestinal haemorrhage complicating the inpatient course especially in children with sepsis or multiple chronic comorbidities and requiring more aggressive hemodynamic support is especially guarded.
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